摘要
目的建立液相色谱-串联质谱法测定人血浆中左旋氨氯地平的浓度,研究2种苯磺酸左旋氨氯地平片的人体药动学及相对生物利用度。方法血浆样品中加入内标硝苯地平,经乙醚-二氯甲烷(3:1)提取,采用液相色谱-串联质谱法。用建立的方法测定20例健康男性受试者单剂量口服苯磺酸左旋氨氯地平受试制剂或参比制剂后的血药浓度,求得药动学参数,并对2种制剂的生物等效性进行评价。结果在0.1～20.0μg·L-1内呈良好的线性关系,方法回收率为99.9%～101.7%,日内、日间RSD均小于15%。单次po 5 mg苯磺酸左旋氨氯地平受试制剂或参比制剂后的tmax分别为(7.80±2.67)和(7.00±2.00)h;ρmax分别为(3.01±1.00)和(3.17±0.93)μg·L-1;t1/2分别为(42.3±17.4)和(39.2±15.0)h;AUC0-t分别为(111.2±29.2)和(116.8±31.1)μg·h·L-1;AUC0-∞分别为(131.3±35.5)和(136.5±32.5)μg·h·L-1。受试制剂对参比制剂的相对生物利用度为(95.9±13.5) %。结论该方法灵敏,无杂质干扰。测得的受试制剂与参比制剂的主要药动学参数之间无明显差异,表明2种制剂在人体内生物等效。
Abstract
OBJECTIVE To determine levamlodipine in human plasma by LC-MS/MS method,and to investigate its pharmacokinetics and relative bioavailability.METHODS Levamlodipine concentrations in plasma extracted with aether: dichlormethane(3:1) were determinated by LC-MS/MS.The test and reference formulations were given to 20 healthy male volunteers.Pharmacokinetics and bioequivalence were evaluated.RESULTS The calibration curve was linear within the range of 0.1-20.0μg·L-1.The method recovery was 99.9%-101.7%.RSDs of intra-day and inter-day were less than 15%.After a single oral dose of 5 mg levamlodipine besilate test or reference tablets,the main pharmacokinetic parameters were as follows:tmax(7.80±2.67) and(7.00±2.00) h,ρmax(3.01±1.00) and(3.17±0.93)μg·L-1,t1/2(42.3±17.4) and(39.2±15.0) h,AUC0-t(111.2±29.2) and (116.8±31.1)μg·h·L-1,AUC0-∞(131.3±35.5) and(136.5±32.5)μg·h·L-1,respectively.Relative bioavailability was(95.9±13.5)%. CONCLUSION The method is sensitive with no endogenous interference.No significant difference exists among the main pharmacokinetic parameters for the test and reference tablets.The two formulations are bioequivalence.
关键词
苯磺酸左旋氨氯地平 /
液相色谱-串联质谱 /
相对生物利用度 /
药动学
{{custom_keyword}} /
Key words
levamlodipine besilate /
LC-MS/MS /
relative bioavailability /
pharmacokinetics
{{custom_keyword}} /
刘茜;李力;杨伦;宋洪涛;李贺;王茜.
液质联用法测定左旋氨氯地平的血药浓度及其片剂的相对生物利用度研究[J]. 中国药学杂志, 2009, 44(10): 774-777
LIU Qin;LI li;YNG Lun;SONG Hong-to;LI He;WNG Qin.
Determination of Levamlodipine in Human Plasma by LC-MS/MS and Its Application to Relative Bioavailability [J]. Chinese Pharmaceutical Journal, 2009, 44(10): 774-777
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] ARROWSMITH J E，CAMPBELL S F，CROSS P E，et al. Long-acting dihydropyridine calcium antagonists. 1. 2-Alkoxymethyl derivatives incorporating basic substituents[J]. J Med Chem，1986，29(9)：1696-1702.
[2] MA Y Y，QIN F，SUN X H，et al. Determination and pharmacokinetic study of amlodipine in human plasma by ultra performance liquid chromatography-electrospray ionization mass spectrometry[J]. J Chromatogr B，2007，43(4)：1540-1545.
[3] ZHANG Y，LIU M，WEN A D，et al. Bioequivalence between two kinds of amlodipine besilate tablets in healthy volunteers[J]. Chin J New Drugs Clin Rem (中国新药与临床杂志)，2006，25(10)：743-746.
[4] YANG H Y，FENG X L，ZHANG Y L. Chiral separation and determination of levamlodipine in human plasma by LC-MS/MS[J]. J Instru Anal (分析测试学报)，2005，24(9)：145-146.
[5] FU C D，XU H N. The stereoselectivity pharmacokinetics of chiral drug[J]. Chin J Clin Pharm(中国临床药学杂志)，1998，7(6)：309-313.
[6] PARK J Y，KIM K A，PARK P W，et al. Pharmacokinetic and pharmacodynamic characteristics of a new S-amlodipine formulation in healthy Korean male subjects：A randomized，open-label，two-period，comparative，crossover study[J]. Clin Ther，2006，28(11)：1837-1847.
{{custom_fnGroup.title_cn}}
脚注
{{custom_fn.content}}
